https://doi.org/10.1007/s10549-024-07291-0
G
Goncagül Akdağ
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
49
Papers
85
Citations
5
h-index
1
i10-index
Goncagül Akdağ is an academic researcher from University of Health Science. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & HER2/EGFR in Cancer Research & Breast Cancer Treatment Studies. The author has an h-index of 5, co-authored 42 publications.
ORCID: 0000-0002-6221-0623Papers by this author
worksThe effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study
2024 · Breast Cancer Research and Treatment · 6 citations
Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)
2024 · European Archives of Oto-Rhino-Laryngology · 4 citations
https://doi.org/10.1007/s00405-024-08744-4
Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study
2025 · Medicina · 2 citations
https://doi.org/10.3390/medicina61010154
The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis
2025 · BMC Cancer · 1 citations
https://doi.org/10.1186/s12885-025-14252-3
Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study
2025 · Scientific Reports · 0 citations
https://doi.org/10.1038/s41598-025-87553-z
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat